Bladder cancer

29 trials 10 recruiting MedDRA PT
29 Registered trials
10 Recruiting
22 Unique sponsors
42 Unique IMPs
22 Commercial trials
Drug classes (ATC)
— ATC code not specified 14
L Oncology (ATC L) 14
B Haematology (ATC B) 1
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 14 substances
Monoclonal antibody (immune) 4 substances
Antimetabolite 3 substances
Antibody-drug conjugate (ADC) 3 substances
Checkpoint inhibitor (PD-L1) 2 substances
Kinase inhibitor 2 substances
Checkpoint inhibitor (CTLA-4) 2 substances
Platinum compound 2 substances
Macrolide / aminoglycoside 2 substances
Alkylating agent 2 substances
Checkpoint inhibitor (PD-1) 1 substance
Supportive / diluent 1 substance
Monoclonal antibody (unknown source) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
PARP inhibitor 1 substance
Topoisomerase II inhibitor 1 substance
Phase III: 8 Phase II: 8 Phase I/II: 3 Phase IV: 2 Phase I: 3 Phase I (Other): 2 Phase I (First in Human): 3

Filter these 29 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 29 trials

Phase III

8 trials
  • AstraZeneca AB Commercial
    DURVALUMAB; TREMELIMUMAB
    2024-510976-19-00 6 countries 2018 n=353
    Ended
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    CISPLATIN; GEMCITABINE HYDROCHLORIDE; NIVOLUMAB
    2024-512158-12-00 11 countries 2018 n=386
    Ended
  • Janssen - Cilag International Commercial
    GEMCITABINE HYDROCHLORIDE
    2023-507685-10-00 7 countries 2024 n=102
    Ended
  • Merck Sharp & Dohme LLC Commercial
    SACITUZUMAB TIRUMOTECAN
    2024-520014-22-00 8 countries 2026 n=265
    Recruiting
  • Urogen Pharma Ltd. Commercial
    MITOMYCIN
    2023-506680-34-00 7 countries 2022 n=161
    Ended
  • Urogen Pharma Ltd. Commercial
    POLOXAMER 407
    2023-507261-25-00 5 countries 2024 n=57
    Ended
  • Unicancer Academic
    IMP not specified
    2024-513707-14-00 1 country 2022 n=646
    Ended
  • Unicancer Academic
    ATEZOLIZUMAB
    2024-517621-54-00 3 countries n=517
    Pending

Phase II

8 trials
  • AstraZeneca AB Commercial
    DURVALUMAB
    2024-519246-75-01 4 countries n=60
    Pending
  • Bayer Consumer Care AG Commercial
    3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; SEVABERTINIB
    2024-517419-62-00 4 countries 2025 n=37
    Recruiting
  • Boehringer Ingelheim International GmbH Commercial
    (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)-6'-METHYL-2-OXO-1,2,3',3A',10',10A'-HEXAHYDRO-1'H-SPIRO[INDOLE-3,2'-PYRROLO[2',3':4,5]PYRROLO[1,2-B]INDAZOLE]-7'-CARBOXYLIC ACID
    2023-506369-79-00 5 countries 2022 n=38
    Ended
  • CatalYm GmbH Commercial
    NIVOLUMAB; SODIUM CHLORIDE; VISUGROMAB
    2024-513957-55-00 1 country 2023 n=31
    Ended
  • Merck Sharp & Dohme LLC Commercial
    MRNA-4157
    2024-517335-46-00 9 countries 2025 n=138
    Recruiting
  • Associacio Per A La Recerca Oncologica Academic
    ANTI-PDCD1 IGG4 HUMANISED MONOCLONAL ANTIBODY; SACITUZUMAB GOVITECAN; SASANLIMAB
    2024-518486-10-00 1 country 2023 n=42
    Ended
  • Fondazione IRCCS Istituto Nazionale Dei Tumori Academic
    SACITUZUMAB GOVITECAN; ZIMBERELIMAB
    2024-516943-14-01 1 country n=62
    Pending
  • Grupo Espanol De Oncologia Genitourinaria-Socug Academic
    CETRELIMAB; ERDAFITINIB
    2024-512573-27-01 3 countries 2023 n=62
    Ended

Phase I/II

3 trials
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB; NIVOLUMAB, RELATLIMAB; RELATLIMAB
    2023-508067-70-00 9 countries 2015 n=1,003
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    IPILIMUMAB; NIVOLUMAB
    2024-516540-25-00 1 country 2013 n=83
    Ended
  • Cyclacel Limited Commercial
    CYC140 MONOHYDROCHLORIDE MONOHYDRATE
    2024-516290-67-00 1 country 2022 n=56
    Ended

Phase IV

2 trials
  • Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino Academic
    HEXAMINOLEVULINATE
    2024-514316-27-00 1 country n=300
    Pending
  • Turku University Hospital Academic
    BLEOMYCIN SULFATE PH. EUR.; CAPECITABINE; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MESNA; OXALIPLATIN
    2024-513437-21-00 1 country 2024 n=250
    Recruiting

Phase I

3 trials
  • BeOne Medicines AG Commercial
    IMP not specified
    2025-523165-19-00 1 country 2026 n=15
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2024-516870-31-00 1 country 2025 n=21
    Recruiting
  • Seagen Inc. Commercial
    IMP not specified
    2023-508469-34-00 2 countries 2020 n=238
    Recruiting

Phase I (Other)

2 trials
  • Exelixis Inc. Commercial
    IMP not specified
    2023-508267-69-00 5 countries 2023 n=222
    Ended
  • Toray Industries Inc. Commercial
    IMP not specified
    2024-513915-28-00 1 country 2019 n=32
    Ended

Phase I (First in Human)

3 trials
  • AstraZeneca AB Commercial
    [11C]AZ14193391; 6-FLUORO-5-[4-[(5-FLUORO-2-METHYL-3-OXO-4H-QUINOXALIN-6-YL)METHYL]PIPERAZIN-1-YL]-N-METHYLPYRIDINE-2-CARBOXAMIDE; DATOPOTAMAB DERUXTECAN; PALACAPARIB; TEMOZOLOMIDE; TRASTUZUMAB DERUXTECAN
    2023-504984-17-00 2 countries 2022 n=176
    Recruiting
  • Engene Inc. Commercial
    DETALIMOGENE VORAPLASMID
    2024-512900-20-00 4 countries 2025 n=79
    Recruiting
  • Salubris Biotherapeutics Inc. Commercial
    JK06
    2024-512421-92-00 2 countries 2025 n=305
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Merck Sharp & Dohme LLC Commercial 3 Phase I, Phase II, Phase III 3
AstraZeneca AB Commercial 3 Phase II, Phase III, Phase I (First in Human) 1
Urogen Pharma Ltd. Commercial 2 Phase III 0
Bristol Myers Squibb International Corporation Commercial 2 Phase I/II 0
Unicancer Academic 2 Phase III 0
BeOne Medicines AG Commercial 1 Phase I 1
Seagen Inc. Commercial 1 Phase I 1
Exelixis Inc. Commercial 1 Phase I (Other) 0
Toray Industries Inc. Commercial 1 Phase I (Other) 0
Bayer Consumer Care AG Commercial 1 Phase II 1
Boehringer Ingelheim International GmbH Commercial 1 Phase II 0
CatalYm GmbH Commercial 1 Phase II 0
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase III 0
Janssen - Cilag International Commercial 1 Phase III 0
Engene Inc. Commercial 1 Phase I (First in Human) 1
Salubris Biotherapeutics Inc. Commercial 1 Phase I (First in Human) 1
Cyclacel Limited Commercial 1 Phase I/II 0
Associacio Per A La Recerca Oncologica Academic 1 Phase II 0
Fondazione IRCCS Istituto Nazionale Dei Tumori Academic 1 Phase II 0
Grupo Espanol De Oncologia Genitourinaria-Socug Academic 1 Phase II 0
New trials by year
2019
1
2020
1
2022
5
2023
4
2024
3
2025
5
2026
2
← All indication landscapes